Immunoglobulins IV (CLAYRIG)

Phase 2Small molecule

AAssistance Publique - Hôpitaux de Paris

Immunoglobulins IV (CLAYRIG) is one of 3 small molecule programs targeting Paraneoplastic Sensory Neuronopathy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Paraneoplastic Sensory NeuronopathyRecruiting

Paraneoplastic Sensory NeuronopathyPhase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Paraneoplastic Sensory Neuronopathy

#DrugCompanyPhaseTrials

Methylprednisolone IV

Roche

Phase 2

1 2

Cyclophosphamide IV

AAssistance Publique - Hôpitaux de Paris

Phase 2

1 3

Immunoglobulins IV (CLAYRIG)

AAssistance Publique - Hôpitaux de Paris

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Paraneoplastic Sensory Neuronopathy

NCT06373211

Clinical

Trials by Indication[1]

Paraneoplastic Sensory Neuronopathy1 trial

Early Immunotherapy with Intravenous Immunoglobulin, Cyclophosphamide and Methylprednisolone in Patients with Anti-Hu-associated Paraneoplastic Sensory Neuronopathy

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT06373211·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Immunoglobulins IV (CLAYRIG). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Immunoglobulins IV (CLAYRIG) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Immunoglobulins IV (CLAYRIG). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAssistance Publique - Hôpitaux de Paris

Immunoglobulins IV (CLAYRIG)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Paraneoplastic Sensory Neuronopathy1 trial

References

Drug Info

Quick Facts

Related News